David E. Adelberg

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

Joseph Chao, Charles S. Fuchs, Kohei Shitara et al. · JAMA Oncology · 2021 · 443 citations · Full text

Medicine, Oncology, Gastrointestinal Oncology +12

KEYNOTE-585: Phase III Study of Perioperative Chemotherapy with or Without Pembrolizumab for Gastric Cancer

Yung‐Jue Bang, Eric Van Cutsem, Charles S. Fuchs et al. · Future Oncology · 2019 · 171 citations · Full text

Medicine, Oncology, Perioperative Medicine +14

Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study

Thierry André, Kai Keen Shiu, Tae Won Kim et al. · Annals of Oncology · 2024 · 105 citations · Full text

Medicine, Oncology, Chemotherapy +16

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

Akihito Kawazoe, Rui‐Hua Xu, Pilar García‐Alfonso et al. · Journal of Clinical Oncology · 2024 · 77 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

Kohei Shitara, Mustafa Özgüroğlu, Y.-J. Bang et al. · Annals of Oncology · 2021 · 67 citations · Full text

Medicine, Oncology, Pharmacology +17